ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,00%
Bitcoin
97.648,37
-0,47%
Brent Oil
76,495
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vertex Pharmaceuticals Inc (VRTX)

  7. Vertex Pharmaceuticals Inc (VRTX) Notícias

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VRTX
DataHoraFonteTítuloCódigoCompanhia
23/12/202418:05Business WireVertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13NASDAQ:VRTXVertex Pharmaceuticals Inc
20/12/202417:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
20/12/202417:46Business WireVertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
20/12/202417:35Business WireVertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive VariantsNASDAQ:VRTXVertex Pharmaceuticals Inc
19/12/202408:00Business WireVertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral RadiculopathyNASDAQ:VRTXVertex Pharmaceuticals Inc
08/12/202414:52Business WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program UpdateNASDAQ:VRTXVertex Pharmaceuticals Inc
19/11/202418:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
15/11/202412:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
05/11/202418:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
05/11/202408:43IH Market NewsBoeing Ends Strike; Leadership Changes at Dollar Tree and Southwest; PLTR, HIMS, and ALAB Soar; MQ and LSCC DeclineNASDAQ:VRTXVertex Pharmaceuticals Inc
04/11/202418:01Business WireVertex Reports Third Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
29/10/202417:05Business WireVertex to Participate in Upcoming November Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
25/10/202414:00Business WireVertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week CongressNASDAQ:VRTXVertex Pharmaceuticals Inc
18/10/202409:00Business WireVertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual MeetingNASDAQ:VRTXVertex Pharmaceuticals Inc
10/10/202417:05Business WireVertex to Announce Third Quarter 2024 Financial Results on November 4thNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202410:00PR Newswire (Canada)Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202410:00PR Newswire (Canada)Vertex annonce l'acceptation par Santé Canada de la soumission de drogue nouvelle pour l'association vanzacaftor/tézacaftor/deutivacaftor, un traitement d'association triple de nouvelle génération pour la fibrose kystiqueNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202408:07Business WireVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceNASDAQ:VRTXVertex Pharmaceuticals Inc
25/09/202416:51PR Newswire (Canada)Santé Canada accorde l'autorisation de mise sur le marché de la première thérapie d'édition génomique CRISPR/Cas9, CASGEVY® (exagamglogène autotemcel), pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusiNASDAQ:VRTXVertex Pharmaceuticals Inc
25/09/202416:50PR Newswire (Canada)Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
22/08/202409:00Business WireVertex to Participate in Upcoming September Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/08/202420:12Business WireVertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in EnglandNASDAQ:VRTXVertex Pharmaceuticals Inc
01/08/202417:01Business WireVertex Reports Second Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
30/07/202414:10Business WireVertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
15/07/202410:00PR Newswire (Canada)Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations raresNASDAQ:VRTXVertex Pharmaceuticals Inc
15/07/202410:00PR Newswire (Canada)Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare MutationsNASDAQ:VRTXVertex Pharmaceuticals Inc
02/07/202409:33Business WireVertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
01/07/202417:05Business WireVertex to Announce Second Quarter 2024 Financial Results on August 1NASDAQ:VRTXVertex Pharmaceuticals Inc
21/06/202416:45Business WireVertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific SessionsNASDAQ:VRTXVertex Pharmaceuticals Inc
20/06/202408:15Business WireVertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®NASDAQ:VRTXVertex Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VRTX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
USIM5
USIMINAS PNA
BOV
INBR32
Inter &
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
GFSA3
GAFISA ON
BOV
BRSR6
BANRISUL PNB
BOV
SEQL3
Sequoia Logistica e Tran... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados